期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 97, 期 3, 页码 377-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2012.12.017
关键词
Alzheimer disease; Amyloid imaging; Posistron emission tomography; A beta levels
资金
- National Health and Medical Research Council of Australia [1011689]
- Science and Industry Endowment Fund
- Austin Hospital Medical Research Foundation
In vivo imaging of amyloid-beta (A beta) with positron emission tomography has moved from the research arena into clinical practice. Clinicians working with cognitive decline and dementia must become familiar with its benefits' and limitations. Amyloid imaging allows earlier diagnosis of Alzheimer disease and better differential diagnosis of dementia and provides prognostic information for mild cognitive impairment. It also has an increasingly important role in therapeutic trial recruitment and for evaluation of anti-A beta treatments. Longitudinal observations are required to elucidate the role of A beta deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据